Intuniv FDA Approval History
FDA Approved: Yes (First approved September 2, 2009)
Brand name: Intuniv
Generic name: guanfacine
Dosage form: Extended Release Tablets
Previous Name: Connexyn
Company: Shire plc
Treatment for: ADHD
Intuniv (guanfacine) is a nonstimulant selective alpha-2A-receptor agonist for the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD).
Development timeline for Intuniv
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.